[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meniere-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meniere-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,83,109,130,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100613890","effects-of-cervical-mobilization-on-dizziness-balance-and-joint-position-sense-in-patients-with-menieres-disease-100613890",false,"NCT07272473","Effects of Cervical Mobilization on Dizziness, Balance, and Joint Position Sense in Patients With Meniere's Disease","Inclusion Criteria:\n\n* Definitive clinical diagnosis of unilateral or bilateral Meniere's disease\n* Age between 18 and 60 years\n* Presence of fluctuating symptoms or chronic imbalance for at least 3 months\n* Cognitive ability to participate in balance rehabilitation tasks (Mini Mental State Examination score ≥ 24)\n* Willingness to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Diagnosis of vertigo not associated with Meniere's disease\n* Presence of another acute medical condition\n* Neurological, psychological, or cognitive dysfunction\n* History of orthopedic surgery within the last 3 months\n* Planned surgical intervention during the rehabilitation program\n* Cervical spine instability\n* Acute cervical trauma\n* Vertebral artery insufficiency","ALL","18 Years","60 Years",{"count":19,"type":20},33,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study will employ a stratified randomization method. Patients presenting to the Afyonkarahisar Health Sciences University Health Application and Research Center, Ear, Nose, and Throat Outpatient Clinic, with a definitive diagnosis of Meniere's disease, unilateral or bilateral involvement, and who consent to participate in the study will be divided into three groups. The control group will receive only their routine Betahistine. Their usual treatment will remain unchanged. The first study group will receive 20 minutes of Vestibular Rehabilitation (VR) and 10 minutes of cervical mobilization in addition to their routine Betahistine. The second study group will receive 30 minutes of VR in addition to Betahistine. The study will last 6 weeks. Participants will be assessed using a sociodemographic information questionnaire, the Dizziness Handicap Inventory (DHI), the Vertigo Symptom Scale (VSS), the Neck Disability Index (NDI), the International Tinnitus Inventory (ITI), balance assessment with the K-Force Plates, and joint position sense and proprioception assessment with the Kinvent Physio K-Move. All assessments will be conducted twice, before and after treatment.",[26],"Meniere Disease",[28,29,30,31,32,33,34],"Endolymphatic hydrops","Postural Balance","Tinnitus","Position Sense","Kinesthesis","Vestibular Sense","Neck Pains","RECRUITING","2025-12-13",{"date":38,"type":39},"2025-12-19","ACTUAL",{"date":41,"type":39},"2025-09-20",{"date":43,"type":20},"2026-05-05",{"name":45,"class":46},"Abant Izzet Baysal University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100471855","effect-of-peripheral-vestibular-disease-location-on-outcomes-following-home-based-virtual-reality-vestibular-therapy-100471855","NCT05424302","Effect of Peripheral Vestibular Disease Location on Outcomes Following Home-based Virtual Reality Vestibular Therapy","Effect of Peripheral Vestibular Pathology Location on the Ability of Home-based Virtual Reality to Improve Symptoms of Peripheral Vestibular Disorders","VR-PVD-RCT","Inclusion Criteria:\n\n* Participants diagnosed with chronic (≥3 months) unilateral or bilateral peripheral vestibular disorders such as vestibular neuritis, labyrinthitis, Ramsay Hunt syndrome, ischemic lesion and trauma.\n* Diagnosis made using caloric testing (≥25% reduced vestibular response) and either ocular vestibular evoked myogenic potential (oVEMP) or cervical vestibular evoked myogenic potential (cVEMP) testing.\n* Participants prescribed vestibular rehabilitation\n* Participants ≥18 years of age\n* Access to an android or iOS smart phone\n\nExclusion Criteria:\n\n* Pregnant participants\n* Participant diagnosed with a central vestibular disorder",true,{"count":58,"type":20},50,[23],"This parallel-group randomized controlled trial aims to determine if the location of the lesion(s) in the vestibular system (unilateral versus bilateral, lateral semi-circular canal versus otolith) impacts the effectiveness of adjunct take-home head-mounted display (HMD) virtual reality (VR) therapy in improving patient symptomatology. Fifty patients meeting inclusion criteria will be recruited from the principal investigator's neurotology clinic. Baseline symptomatology questionnaires will be completed, followed by random allocation to virtual reality and control groups. Vestibular rehabilitation and virtual reality protocols will be adhered to for 4 to 8 weeks, followed by symptomatology questionnaires. Data analysis will be conducted to answer the study's objectives.",[62,63,26,64,65,66,67],"Peripheral Vestibular Disorder","Benign Paroxysmal Positional Vertigo","Vestibular Neuritis","Vestibular Neuronitis","Labyrinthitis","Herpes Zoster Oticus",[69,70,71,72,73,64,65,66,67],"Virtual reality","Video games","Peripheral vestibular disorders","Benign paroxysmal positional vertigo","Meniere disease","2024-08-13",{"date":76,"type":39},"2024-08-15",{"date":78,"type":39},"2024-06-01",{"date":80,"type":20},"2026-09",{"name":82,"class":46},"University of British Columbia",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100557924","phase-2-laser-acupuncture-for-meniere-disease-100557924","NCT06544434","Laser Acupuncture for Meniere Disease","Laser Acupuncture for Meniere Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical diagnosis of meniere disease.\n\nExclusion Criteria:\n\n1. Serious mental illness or social problems, and neurological disorders, and systemic diseases, such as malignant tumors, and other serious consumptive diseases.\n2. Planning for pregnancy, those in pregnancy, or those who were lactating.","65 Years",{"count":92,"type":20},324,[94],"PHASE2","Objective: To evaluate the effect of laser acupuncture for the patients Meniere disease.\n\nMethods: We enrolled 324 patients at Beijing Tongren Hospital. Patients completed outcome measures at baseline, 3 months, 6 months, and 12 months. Video head impulse test (vHIT), The Caloric Test, Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI), Pure Tone Audiometry (PTA), and visual scale of ear stuffiness to evaluate the therapeutic effects. A difference of P \\\u003C 0.05 was considered statistically significant.",[26],[26,98,99],"RCT","Laser acupuncture","2024-08-06",{"date":102,"type":39},"2024-08-09",{"date":104,"type":39},"2021-05-01",{"date":106,"type":20},"2024-10-20",{"name":108,"class":46},"Beijing Tongren Hospital",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100390931","imaging-of-endolymphatic-hydrops-at-7t-mri-100390931","NCT04370366","Imaging of Endolymphatic Hydrops at 7T MRI","Imaging Endolymphatic Hydrops at 7T MRI: Validation of Internal Inner Ear Structures on T2w Imaging as Markers of Endolymphatic Hydrops and a Comparison of Diagnostic Outcomes With 3T MRI","Inclusion Criteria\n\n* Male or female, 18 years of age or older\n* The capacity to understand the patient information sheet and the ability to provide written informed consent\n* Unilateral audio-vestibular symptoms which satisfy 2015 Barany criteria for unilateral Meniere's Disease of less than 5 years duration\n* Would be offered clinical MRI scanning for confirmation of a Meniere's disease diagnosis as part of standard of care\n\nExclusion Criteria:\n\n* Standard contraindications to 7T MRI\n* Known allergy to Gadolinium contrast\n* Calculated GFR \\\u003C 30 mls\u002Fmin\n* Previous temporal bone surgery or trauma\n* Other known temporal bone pathology\n* Requirement for early post gadolinium sequences (e.g. autoimmune inner disease as a differential diagnosis)",{"count":117,"type":20},16,"OBSERVATIONAL","Imaging endolymphatic hydrops with 7T Sodium Imaging and 1.5 T gadolinium enhanced imaging: a comparison of diagnostic outcomes with 3T MRI\n\nDuration of study 24 months\n\nStudy design Prospective cohort study\n\nNumber of patients 16 patients\n\n1. To evaluate whether imaging both 1.5T and 3T have an equivalent performance in terms of diagnosing MD ears with delayed post gadolinium enhanced MRI (applying quantitative and semi-quantitative analysis)\n2. To compare the diagnostic performance of Sodium Imaging at 7T (applying semi-quantitative analysis) with that of delayed post gadolinium enhanced 3T MRI in distinguishing symptomatic from asymptomatic Meniere's Disease (MD) ears.",[26],"2024-03-05",{"date":123,"type":39},"2024-03-06",{"date":125,"type":39},"2023-07-01",{"date":127,"type":20},"2026-07-01",{"name":129,"class":46},"King's College Hospital NHS Trust",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":56,"sex":15,"minAge":16,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100504682","phase-3-the-effecttiveness-of-intratympanic-methylprednisolon-injections-compared-to-placebo-in-the-treatment-of-vertigo-attacks-in-menieres-disease-100504682","NCT05851508","The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease","A Multicenter, Double-blinded, Randomized, Placebo-controlled Trial to Compare the Effectiveness of Intratympanic Injections methylPREDnisolon Versus Placebo in the Treatment of Vertigo Attacks in MENière's Disease (PREDMEN Trial).","PREDMEN","Inclusion criteria:\n\n• Unilateral, definite MD according to the diagnostic criteria derived from the American Academy Otolaryngology Head and Neck Surgery, Classification Committee of the Bárány Society, European Academy of Otology and Neurotology and International Classification of Vestibular Disorders published in 2015 \\[7\\] (see Appendix 1):\n\nDefinite MD Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours, AND Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear on at least one occasion before, during or after one of the episodes of vertigo, AND Fluctuating aural symptoms (hearing, tinnitus, or fullness) in affected ear (not better accounted for by another vestibular diagnosis)\n\n* age \\> 18 years at the start of the trial.\n* ≥ 4 vertigo attacks over the last 6 months.\n* willing to adhere to daily trial medications and the follow-up assessments.\n\nExclusion criteria\n\nA potential subject who meets any of the following criteria will be excluded:\n\n* bilateral MD\n* severe disability (e.g. neurological, orthopaedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow-up.\n* active additional neuro-otologic disorders that may mimic MD (e.g. vestibular migraine, recurrent vestibulopathy, phobic postural vertigo, vertebro-basilar TIAs, acoustic neuroma).\n* otitis media with effusion based on tympanogram results.\n* history of intratympanic injections with corticosteroid less than 6 months ago.\n* history of intratympanic injections with gentamicin or ear surgery for treating MD.\n* pregnant women and nursing women.","100 Years",{"count":140,"type":20},148,[142],"PHASE3","Ménière's disease is an inner ear disorder in which patients suffer from attacks of vertigo, tinnitus and hearing loss. To date, it is unclear what the best treatment for this condition is. Giving injections in the inner ear with the adrenal cortical hormone methylprednisolone is a treatment that is already widely used, but still there is insufficient evidence in the effectiveness of this treatment. This multicenter trial compares a patient group which receives injections of methylprednisolone to a patient group which receives placebo injections. Subsequently, dizziness, tinnitus, hearing loss and quality of life will be assed and compared for the above mentioned groups, over a period of one year.",[26],[146,147,148,149,150,151,152,153],"Meniere's disease","Methylprednisolon","Intratimpanic corticosteroids","Dizziness","Hearing loss","tinnitus","aural fullness","randomized control trial","2023-11-28",{"date":156,"type":39},"2023-12-04",{"date":158,"type":39},"2023-10-01",{"date":160,"type":20},"2027-02-01",{"name":162,"class":46},"Leiden University Medical Center",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":56,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100464041","meniers-disease---bone-density-study-100464041","NCT05322538","Menier's Disease - Bone Density Study","Inclusion Criteria:\n\n* Definite Meniere's disease\n\nExclusion Criteria:\n\n* hyperthyroidism\n* hyperparathyroidism\n* acromegaly\n* hypogonadism\n* diabetes melitus\n* chronic renal failure\n* alcoholism\n* cushing syndrome\n* rheumatoid arthritis\n* systemic lupus erythematosus\n* ankylosing spondylitis\n* inflammatory bowel disease\n* obstructive lung disease\n* sarcoidosis\n* amyloidosis\n* celiac disease.\n* chronic treatment with bisphosphonates\n* chronic treatment with glucocorticoids\n* chronic treatment with androgen deprivation therapy\n* chronic treatment with gonadotropin releasing hormone agonist chronic treatment with aromatase inhibitor chronic treatment with loop diuretics chronic treatment with proton pump inhibitors chronic treatment with anti-seizure drugs chronic treatment with warfarin chronic treatment with SSRI chronic treatment with alpha or beta-blockers",{"count":170,"type":20},60,[23],"Meniere's disease is a progressive and debilitating inner ear disease characterised by vertigo and hearing loss. Several studies have linked Menierws disease with lower bone density and lower vitamin D levels. In the current prospective study definite Meniere's patients will be followed over a period of 2 year, during which repetitive measurements of bone density, vitamin D plasma levels, blood pressure as well as hearing and vestibular tests will be made. Results will be compared to healthy controls.",[26,174,175,176,177],"Osteoporosis","Osteopenia","Vitamin D Deficiency","Vestibular Disorder","NOT_YET_RECRUITING","2022-08-02",{"date":181,"type":39},"2022-08-03",{"date":183,"type":20},"2022-10-01",{"date":185,"type":20},"2028-12-31",{"name":187,"class":46},"HaEmek Medical Center, Israel"]